A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumanniibloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol

•Cefiderocol showed a high failure rate for XDR-AB infections in the CREDIBLE-CR trial.•A case series of ICU patients receiving cefiderocol for XDR-AB infections was analysed.•Microbiological failure occurred in 54% of patients.•Microbiological failure rate was higher in patients achieving suboptimal fCmin/MIC.•Attainment of suboptimal PK/PD target could explain the low eradication rate.•Higher PK/PD targets could be desirable in VAP given the low penetration into ELF.